Menu
Close
About Us
Company Overview
Our History
Leadership
Board of Directors
Scientific Advisory Board
Our Advisors
Therapeutic Areas
Acute Myocarditis
Recurrent Pericarditis
Viral Infection and CVD
Heart Failure
Research
R&D Partners
Our Science
Resources
Pipeline
CardiolRX™
Investors
Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
Corporate Governance
Contact Us
News
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
June 29, 2022
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
June 27, 2022
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
June 09, 2022
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors
May 19, 2022
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis
May 17, 2022
Cardiol Therapeutics Announces Year-End 2021 Update on Operations
March 24, 2022
Cardiol Therapeutics to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
March 22, 2022
Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors
March 15, 2022
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial
March 01, 2022
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
January 19, 2022
Page 1 of 10
1
2
3
4
5
...
10
...
»
Last »
